ELUCIDATING RESISTANCE MECHANISM TO PARP INHIBITORS FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES IN HIGH-GRADE SEROUS OVARIAN CANCER

被引：1
|
作者：
Kulbe, Hagen [1 ]
Kassuhn, Wanja [2 ,3 ,4 ,5 ]
Ringel, Frauke [2 ,3 ,4 ,5 ]
Welsch, Gabriele [2 ,3 ,4 ,5 ]
Treffkorn, Peggy [2 ,3 ,4 ,5 ]
Taube, Eliane [2 ,3 ,4 ,5 ]
Horst, David [2 ,3 ,4 ,5 ]
Sehouli, Jalid [2 ,3 ,4 ,5 ]
Braicu, Elena [2 ,3 ,4 ,5 ]
机构：
[1] Charite Univ Med Berlin, Dept Gynecol, Campus Virchow Clin, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Berlin Inst Hlth, Berlin, Germany
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-ESGO.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
416
引用
收藏
页码：A79 / A79
页数：1
相关论文
共 50 条
  • [21] High-throughput approaches for precision medicine in high-grade serous ovarian cancer
    Meinusha Govindarajan
    Christoph Wohlmuth
    Matthew Waas
    Marcus Q. Bernardini
    Thomas Kislinger
    Journal of Hematology & Oncology, 13
  • [22] EXPLORATION OF RESISTANCE OF PARP INHIBITOR THERAPY IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENT-DERIVED XENOGRAFTS.
    Ye, L.
    Topp, M.
    Boehm, E.
    Hadley, A.
    Cook, M.
    Heong, V.
    Pyman, J.
    McNally, O.
    Ananda, S.
    Harrell, M.
    Alsop, K.
    Bowtell, D. D.
    Johnson, N.
    Kaufmann, S. H.
    Swisher, E. M.
    Wakefield, M.
    Scott, C. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 407 - 408
  • [23] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [24] High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
    Lisio, Michael-Antony
    Fu, Lili
    Goyeneche, Alicia
    Gao, Zu-hua
    Telleria, Carlos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04)
  • [25] Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
    Konecny, Gottfried E.
    Wang, Chen
    Hamidi, Habib
    Winterhoff, Boris
    Kalli, Kimberly R.
    Dering, Judy
    Ginther, Charles
    Chen, Hsiao-Wang
    Dowdy, Sean
    Cliby, William
    Gostout, Bobbie
    Podratz, Karl C.
    Keeney, Gary
    Wang, He-Jing
    Hartmann, Lynn C.
    Slamon, Dennis J.
    Goode, Ellen L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (10):
  • [26] The use of novel PP2A activators in combination with PARP inhibitor for the treatment of high-grade serous ovarian cancer
    Armstrong, A. J.
    Joseph, P.
    Nagaraj, A. B.
    Nagel, C. I.
    Nakayama, J.
    Waggoner, S. E.
    Zanotti, K. M.
    DiFeo, A.
    Narla, G.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 73 - 73
  • [27] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
  • [28] Targeting Protein Phosphatase 2A in Combination with PARP inhibitors for the treatment of high-grade serous epithelial ovarian cancer.
    Avelar, Rita A.
    Armstrong, Amy
    Narla, Goutham
    DiFeo, Analisa
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 55 - 56
  • [29] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [30] The genesis and evolution of high-grade serous ovarian cancer
    Bowtell, David D. L.
    NATURE REVIEWS CANCER, 2010, 10 (11) : 803 - 808
12345